Navigation Links
Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Date:12/21/2007

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The initial Phase 1 clinical trial of LX1032 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers. This study is designed to evaluate the safety, tolerability, and pharmacokinetics of LX1032. Lexicon expects to initiate clinical trials with LX1032 following FDA review.

"We believe LX1032 has the potential to be an important new therapy in an area of high unmet medical need," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "LX1032 may offer important benefits to patients with carcinoid syndrome, who have very limited treatment options."

Carcinoid syndrome is the result of metastatic carcinoid tumors that usually originate from enterochromaffin cells in the lining of the gastrointestinal tract. These tumors secrete large amounts of serotonin, which causes a variety of symptoms that often includes severe diarrhea and abdominal discomfort. Carcinoid tumors are a type of neuroendocrine tumor and, according to the American Cancer Society, about 11,000 to 12,000 neuroendocrine tumors and neuroendocrine cancers are diagnosed each year in the United States. About 10% of people with carcinoid tumors will develop carcinoid syndrome.

The target for LX1032 was identified through the Genome5000(TM) project, Lexicon's program to identify the function of 5,000 druggable genes in the human genome. LX1032
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... lessons often have it that American Indians largely were ... pox, influenza and tuberculosis brought to the New World ... about 20 million people lived in the Americas shortly ... were killed by European diseases., But new research led ... and Johannes Krause of the University of Tubingen in ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that the vascular access device ... , India and China ... equal to the size of the United States ... experience much faster growth as a result of strong economic expansion, ... key findings from Decision Resources Group,s coverage of the BRIC vascular ...
(Date:8/20/2014)... 2014 /PRNewswire-iReach/ -- A case study from Intel ... school,s bioengineering department and the Intel® Internet of ... Academic Program, UCSD,s research focuses on exploring the ... Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... of Dr. Todd P. Coleman , Associate ...
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... (PHPG) today reported its consolidated, audited, financial,results for its ... in fiscal year 2007 were a record at $15,100,000 ... the year was our,highest ever at $17,802,000 as was ... 2006, respectively., Pre-tax income for the year was ...
... March 31 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: ... marketing and distribution partner in Japan, has,received approval ... Japanese Ministry of Health, Labour and Welfare,(MHLW) for ... MPS,VI)., "We are proud to work with ...
... Initial Proceeds to be Used for Marketing in ... -- China Kangtai,Cactus Biotech Inc. (the "Company") (OTC ... and marketer of a,variety of cactus-based consumer products ... into an equity purchase agreement with T Squared,Investments ...
Cached Biology Technology:Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 2Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 3Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 4Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 5Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 6Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 7Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 8Photonic Products Group, Inc. Reports Record Financial Results for FY 2007 9Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing 2
(Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
(Date:8/19/2014)... a new implantable tissue scaffold coated with bone growth ... When applied to bone injuries or defects, this coated ... that looks and behaves just like the original tissue. ... dramatic improvement over the current standard for treating bone ... the patient,s body a painful process that does ...
(Date:8/19/2014)... 19, 2014 ) -- Scientists at the Houston Methodist ... and transfer single cells using a pipette -- a ... this engineering feat and preliminary test results in a ... Chemical Society . , "Studying single cells and their ... research," said nanomedicine department. faculty member Lidong Qin, Ph.D., ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Engineering new bone growth 2Engineering new bone growth 3Moving single cells around -- accurately and cheaply 2
... Canadian agriculture is faced with great opportunities, but ... expert panel convened by the Council of Canadian ... in Canada can be more sustainably managed by ... management strategies, adopting effective governance mechanisms, and harnessing ...
... Feb. 26, 2013   Althea Technologies, Inc. , ... services, and Profectus BioSciences Inc , a ... of a manufacturing supply agreement for plasmid DNA ... quantities of cGMP (current Good Manufacturing Practice) manufactured ...
... of Kansas researchers have found that the infants of mothers ... DHA during pregnancy weighed more at birth and were less ... 34 weeks gestation than infants of mothers who were given ... the dietary supplement during pregnancy. Susan CarlsonThe results are ...
Cached Biology News:Report: 'Water and Agriculture in Canada: Towards Sustainable Management of Water Resources' 2Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production 2Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production 3Prenatal DHA reduces early preterm birth, low birth weight 2
Phospho-FAK (Tyr576/577) Antibody...
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Biology Products: